According to CoinMeta, Hengrui Medicine announced that its subsidiary, Guangdong Hengrui Medicine Co., Ltd., has received the "Drug Clinical Trial Approval Notice" for the SHR-1139 injection issued by the National Medical Products Administration. They will soon commence clinical trials for palmoplantar pustulosis. The SHR-1139 injection is a bispecific antibody independently developed by the company targeting IL-23p19 and IL-36r. Currently, there are no similar drugs approved for market sale either domestically or internationally. The total investment in research and development for this project amounts to approximately 163 million yuan. This drug still needs to complete clinical trials and regulatory approvals before it can be launched, which involves uncertainties.